The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination
Open accessAbstract
Tumour necrosis factor is linked to the pathophysiology of various neurodegenerative disorders including multiple sclerosis. Tumour necrosis factor exists in two biologically active forms, soluble and transmembrane. Here we show that selective inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis. Treatment with XPro1595, a selective soluble tumour necrosis factor blocker, improves the clinical outcome, whereas non-selective inhibition of both forms of tumour necrosis factor with etanercept does not result in protection. The therapeutic effect of XPro1595 is associated with axon preservation and improved myelin compaction, paralleled by increased expression of axon-specific molecules (e.g. neurofilament-H) and reduced expression of non-phosphorylated neurofilament-H which is associated with axon damage. XPro1595-treated mice show significant remyelination accompanied by elevated expression of myelin-specific genes and increased numbers of oligodendrocyte precursors. Immunohistochemical characterization of tumour necrosis factor receptors in the spinal cord following experimental autoimmune encephalomyelitis shows tumour necrosis factor receptor 1 expression in neurons, oligodendrocytes and astrocytes, while tumour necrosis factor receptor 2 is localized in oligodendrocytes, oligodendrocyte precursors, astrocytes and macrophages/microglia. Importantly, a similar pattern of expression is found in post-mortem spinal cord of patients affected by progressive multiple sclerosis, suggesting that pharmacological modulation of tumour necrosis factor receptor signalling may represent an important target in affecting not only the course of mouse experimental autoimmune encephalomyelitis but human multiple sclerosis as well. Collectively, our data demonstrate that selective inhibition of soluble tumour necrosis factor improves recovery following experimental autoimmune encephalomyelitis, and that signalling mediated by transmembrane tumour necrosis factor is essential for axon and myelin preservation as well as remyelination, opening the possibility of a new avenue of treatment for multiple sclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
TNFα promotes proliferation of oligodendrocyte progenitors and remyelination
Arnett, H. A., Mason, J., Marino, M., Suzuki, K., Matsushima, G. K., & Ting, J. P.-Y. (2001) · Nature Neuroscience · doi:10.1038/nn738 · Cited by 1,012
He, P., Zhong, Z., Lindholm, K., Berning, L., Lee, W., Lemere, C., Staufenbiel, M., Li, R., & Shen, Y. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200705042 · Cited by 390
Arnett, H. A., Wang, Y., Matsushima, G. K., Suzuki, K., & Ting, J. P.-Y. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-30-09824.2003 · Cited by 190
Cited by
Neuroinflammation, Stroke, Blood-Brain Barrier Dysfunction, and Imaging Modalities
Candelario-Jalil, E., Dijkhuizen, R. M., & Magnus, T. (2022) · Stroke · doi:10.1161/strokeaha.122.036946 · Cited by 953
Interrelation of Oxidative Stress and Inflammation in Neurodegenerative Disease: Role of TNF
Fischer, R., & Maier, O. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/610813 · Cited by 731
TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects
Probert, L. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.038 · Cited by 495
Post-stroke inflammation—target or tool for therapy?
Lambertsen, K. L., Finsen, B., & Clausen, B. H. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1930-z · Cited by 465
Role of TNF–TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications
Yang, S., Wang, J., Brand, D. D., & Zheng, S. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00784 · Cited by 410
TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis
Gregory, A. P., Dendrou, C. A., Attfield, K. E., Haghikia, A., Xifara, D. K., Butter, F., Poschmann, G., Kaur, G., Lambert, L., Leach, O. A., et al. (2012) · Nature · doi:10.1038/nature11307 · Cited by 384
Apoptotic cell death in disease—Current understanding of the NCCD 2023
Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J. M., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01153-w · Cited by 361
CNS Demyelination with TNF-α Blockers
Kemanetzoglou, E., & Andreadou, E. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0742-1 · Cited by 319
Body fluid biomarkers in multiple sclerosis
Comabella, M., & Montalban, X. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70233-3 · Cited by 258
Brambilla, R. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01980-7 · Cited by 246
Self-citationShieh, C., Heinrich, A., Serchov, T., van Calker, D., & Biber, K. (2014) · Glia · doi:10.1002/glia.22628 · Cited by 179
Madsen, P. M., Motti, D., Karmally, S., Szymkowski, D. E., Lambertsen, K. L., Bethea, J. R., & Brambilla, R. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.0211-16.2016 · Cited by 161
Self-citationCunha, M. I., Su, M., Cantuti-Castelvetri, L., Müller, S. A., Schifferer, M., Djannatian, M., Alexopoulos, I., van der Meer, F., Winkler, A., van Ham, T. J., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191390 · Cited by 160
Rawji, K. S., Young, A. M. H., Ghosh, T., Michaels, N. J., Mirzaei, R., Kappen, J., Kolehmainen, K. L., Alaeiilkhchi, N., Lozinski, B., Mishra, M. K., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02129-7 · Cited by 153
“As we found that niacin was able to significantly upregulate the secretion of several pro-inflammatory cytokines in vitro, including TNF-α which has been shown to be toxic in its soluble form through TNFR1 on oligodendrocytes [4], we were concerned that niacin treatment in middle-aged mice may exacerbate neurotoxicity.”
BackgroundCueva Vargas, J. L., Osswald, I. K., Unsain, N., Aurousseau, M. R., Barker, P. A., Bowie, D., & Di Polo, A. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.1273-15.2015 · Cited by 132
“Soluble TNF binds primarily to TNFR1, and mediates apoptosis and chronic inflammation (Holtmann and Neurath, 2004; Brambilla et al., 2011; Novrup et al., 2014), whereas membrane-bound TNF displays higher affinity for TNFR2 and regulates immunity against pathogens, resolution of inflammation, and myelination (Pasparaki…”
BackgroundInfluentialPatel, A. G., Nehete, P. N., Krivoshik, S. R., Pei, X., Cho, E. L., Nehete, B. P., Ramani, M. D., Shao, Y., Williams, L. E., Wisniewski, T., et al. (2021) · Brain · doi:10.1093/brain/awab129 · Cited by 44
Ferro, A., Qu, W., Lukowicz, A., Svedberg, D., Johnson, A., & Cvetanovic, M. (2018) · PLOS ONE · doi:10.1371/journal.pone.0200013 · Cited by 26
Pericyte-derived fibrotic scarring is conserved across diverse central nervous system lesions.
Dias, D. O., Kalkitsas, J., Kelahmetoglu, Y., Estrada, C. P., Tatarishvili, J., Ernst, A., Huttner, H. B., Kokaia, Z., Lindvall, O., Brundin, L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.30.068965
White Matter in Crisis: Oligodendrocytes and the Pathophysiology of Multiple Sclerosis
García-Domínguez, M. (2025) · Cells · doi:10.3390/cells14181408 · Cited by 13
“TNF-α , notably in its soluble form (sTNF), signals through TNFR1 to activate NF-κ B pathways, leading to pro-apoptotic and anti-differentiation effects in OPCs [135].”
Metadata
- Authors
- Brambilla, R., Ashbaugh, J. J., Magliozzi, R., Dellarole, A., Karmally, S., Szymkowski, D. E., & Bethea, J. R.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-08-29
- Volume
- 134
- Issue
- 9
- Pages
- 2736-2754
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2138685136
- Cited by
- 210
- References
- 4
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.